+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07544862

Prospective Study Evaluating Stapokibart Injection for Adults with Moderate-to-Severe Atopic Dermatitis

Led by Chengdu Kangnuoxing Biopharma,Inc. · Updated on 2026-06-10

1000

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of Stapokibart Injection in adults with moderate-to-severe atopic dermatitis AD. This prospective, open-label study aims to provide information on how patients respond to this biological treatment over a one-year period. Participants will receive Stapokibart through subcutaneous injections. The study observes patients who have been prescribed this treatment independently by their physician according to China-specific guidelines. The treatment period lasts up to 52 weeks, during which safety and reaction rates are closely monitored. During the study, participants will have assessments to track adverse reactions from enrollment through the full treatment duration. Researchers will collect data on side effects and overall safety. The study is sponsored by Chengdu Kangnuoxing Biopharma, Inc. and is expected to be completed by February 2028.

CONDITIONS

Brief Title

A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

Research Team

Q

Qian Jia

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here